Repros Therapeutics, Inc. (RPRX)

[hiwatt1959]

The last time Rprx supplied additional data to FDA after they had changed meeting type from B to C (11-2014), the stock rallied $3 dollars a share, or at the time 50%. We rallied to $3.45 last year on Proellex V p2 data. A green light in the next month from FDA on P3 could get us back in $4 range. We could also in the next month see day 120 answers and restarting of EU clock, as well as conclusion of Enclomiphene p2b 15 month benefit study.